NEW YORK (GenomeWeb News) – Roche has received the CE-IVD Mark for its new dual-target HIV-1 test allowing it to be used for clinical use throughout the European Union, the firm said today.
 
The firm’s Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 simultaneously amplifies and detects two separate regions of the HIV-1genome, which Roche said enables reliable results even when mutations are present. The test also uses real-time PCR to quantify the amount of HIV-1RNA in a patient’s blood.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.